Slide 1: Cerus Corporation
Cerus Corporation April 2026 Not to be Reproduced
Slide 2: Forward Looking Statements
Forward Looking Statements Except for the historical statements contained herein, this presentation contains forward-looking statements concerning Cerus’ products, prospects and expected results, including statements relating to: Cerus’ 2026 annual product revenue guidance, IFC revenue guidance and
Slide 3: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures This presentation includes certain financial information presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and also on a non-GAAP basis, including adjusted EBITDA and the percentage growth in EMEA product revenue, excluding the impac
Slide 4: Why Cerus?
Why Cerus? • Market leader in pathogen reduction technologies for transfused blood components. • First mover advantage and significant barriers to entry for competition. • TAMs > $7B addressing largely unmet need in blood safety • Longstanding and growing customer base contributes to recurring reven
Slide 5: Our Mission
Our Mission Establish INTERCEPT as the standard of care for transfused blood components globally and enable our customers to do everything in their power to deliver safe and effective blood products to patients. Not to be Reproduced
Slide 6: One of the Most Common Procedures
One of the Most Common Procedures • Nearly 16 million blood components are transfused each year in the U.S.1 • Every 2 seconds someone in the U.S. needs blood and or platelets.1 • 1 in 7 hospital patients needs blood.1 • Globally, approximately 119 million blood donations are collected worldwide.2 •
Slide 7: A Single Donation of Whole Blood
A Single Donation of Whole Blood can be used to make four major components • Platelets • Plasma • Cryoprecipitate • Red Cells Each component carries the potential risk of transmitting an infection from a wide range of contaminants, resulting in serious and sometimes fatal outcomes for patient recipi
Slide 8: Emerging Pathogens: Is Testing a Sustainable Solution?
Emerging Pathogens: Is Testing a Sustainable Solution? Development time, cost, continual emergence of new pathogens 30 years of testing = protection against 11 agents HIV, Hepatitis B, Hepatitis C, HTLV, bacteria, West Nile virus, T. Cruzi, Syphilis, Babesiosis, Zika, Leukocytes Zika Babesiosis Cost
Slide 9: A Paradigm Shift from Reactive Testing: INTERCEPT Blood System
A Paradigm Shift from Reactive Testing: INTERCEPT® Blood System for Platelets & Plasma Pathogen Reduction System INTERCEPT crosslinks DNA and RNA Enveloped viruses to prevent pathogen replication Non-enveloped Potential Pathogens INTERCEPT viruses in Donated Platelet Platelet component Gram-negative
Slide 10: Large & Growing Global Addressable Market Opportunity for INTERCEPT
Large & Growing Global Addressable Market Opportunity* for INTERCEPT Addressable Markets for $5.0B Worldwide Platelet Market Commercially Available INTERCEPT Products $1.3B Potential TAM Growth Today 5-7 Years $0.7B Global $1.3 B >$1.5 B U.S. ~$160 MM >$200 MM $300MM $206.1MM Cerus 2025 Expect mid s
Slide 11: Cerus’ Current Products and Development Pipeline
Cerus’ Current Products and Development Pipeline INTERCEPT Blood Systems Early Development Registration Studies Regulatory Commercially Available Commercially available in the U.S. Commercially available in Europe1 Platelets Commercially available in Latin America2 Joint venture with Shandong Zhongb
Slide 12: Global Reach with Sales in Approximately 40 Countries
Global Reach with Sales in Approximately 40 Countries Cerus Europe BV Amersfoort, Netherlands Corporate headquarters Concord California Cerus ZBK Biomedical Joint venture w/Shandong Zhongbaokang Medical Zibo, China Cumulative kit sales for >20 million INTERCEPT treated doses of platelets & plasma 12
Slide 13: 2025 Product Revenue and 2026 Product Revenue Guidance
2025 Product Revenue and 2026 Product Revenue Guidance* $240 $224-228* $220 $206.1 $200 2026 product revenue guidance range: Product Revenue ($ million) $180.3 $180 $224 million to $228 million* $162.0 $160 $156.4 Includes 2026 IFC∞ revenue guidance range: $140 $130.9 $20 million to $22 million* $12
Slide 14: Platelets and Plasma
Platelets and Plasma 14 Not to be Reproduced
Slide 15: Treatment Process - INTERCEPT Blood System for Platelets and Plasma
Treatment Process - INTERCEPT Blood System for Platelets and Plasma 2 Inactivate* INT200 UVA Illuminator* (A similar treatment set is used for platelets.) *INT200 displayed in the images. CE Mark approved in the EU. Not approved for commercial sale in the U.S. and Canada. 15 Not to be Reproduced
Slide 16: INTERCEPT Blood System for Platelets
INTERCEPT Blood System for Platelets Protects Patients* • Proactive, broad-spectrum inactivation of pathogens (bacteria, viruses, protozoans, leukocytes)1 • Reduced transfusion-transmitted infections (TTIs) and no fatalities attributed to INTERCEPT treated platelets (INTERCEPT Platelets) in publishe
Slide 17: INT200 - Next Generation LED Based Illumination Device
INT200 - Next Generation LED Based Illumination Device • Intuitive Design, Simplified Handling • Touch Screen Navigation, Intuitive Software • Improved Tray Design • Intelligent Scanning • Custom Reporting • Compact Design • Streamlined for a Faster Workflow • Select regulatory approvals to date • C
Slide 18: New BCA Group Purchasing Agreement
New BCA Group Purchasing Agreement • Effective January 1st, 2026. • Largest blood supply cooperative in the U.S. • 60+ community blood center members representing ~50% of the U.S. market (1.35 MM platelets). • Current INTERCEPT Platelet penetration into BCA member blood centers estimated at ~30-35%.
Slide 19: Opportunities for Expansion in EMEA
Opportunities for Expansion in EMEA • 2025 EMEA revenue of $67.4MM, +20% • Currently the standard of care in multiple European countries Austria, Belgium, France, & Switzerland • Ongoing rollout of INT200 Expect to convert entire installed base of (currently ~400) over course of next three years
Slide 20: Platelet Opportunities Beyond EMEA
Platelet Opportunities Beyond EMEA U.S. (reference) • ~2.7MM platelets China • ~2.3MM platelets Brazil • ~500K platelets Japan • ~850K platelets South Korea • ~500K platelets 20 Not to be Reproduced
Slide 21: Be Ready. When Minutes Matter
Be Ready. When Minutes Matter ® Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT® Fibrinogen Complex, IFC) produced from the Not to be Reproduced INTERCEPT® Blood System for Cryoprecipitation MKT-EN 00472-02, v9.0 *INTERCEPT Fibrinogen Complex is available for immediate use for up to
Slide 22: Hemorrhage is a Leading Cause of Preventable Death
Hemorrhage is a Leading Cause of Preventable Death1 #1 ~40% 1.6 Cause Hours Trauma is the #1 cause of death Of these, ~40% are The median time to death from in adults <45 years old2 the result of bleeding2 exsanguination* is 1.6 hours3,4 Trauma5,6 Cardiac (CV) Surgery7 Postpartum Hemorrhage8 Combat9
Slide 23: What is INTERCEPT Fibrinogen Complex (IFC)?
What is INTERCEPT® Fibrinogen Complex (IFC)? • INTERCEPT® Fibrinogen Complex is a pathogen reduced blood component for fibrinogen supplementation • Approved to treat and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency • Immediate*, enriched source of key fact
Slide 24: Shorter Turnaround Times (TAT) & Minimized Wastage
Shorter Turnaround Times (TAT) & Minimized Wastage IFC accelerates availability, minimizes wait times and increases reliability and predictability of blood component delivery. Barnes-Jewish 1 C 2 3 Hospital 4 40 min 10 min Order to Issue IFC reduces blood component wastage, improving blood stewardsh
Slide 25: The cost of thawing cryo AHF
The cost of thawing cryo AHF OR Costs of Cryo If a patient is in the OR, bleeding and needs AHF Wait Time fibrinogen, waiting an additional 24 minutes to thaw cryo AHF costs approximately $1,200 $1200 ($50 per minute X 24 minutes) This estimate does not include the costs of the additional bloo
Slide 26: INTERCEPT Red Blood Cells Development Program
INTERCEPT Red Blood Cells Development Program* * INTERCEPT Red Blood Cells are in development and are not currently licensed for sale in any geography. Not to be Reproduced
Slide 27: INTERCEPT RBC Clinical Development Program
INTERCEPT RBC Clinical Development Program1 Successfully Completed Ongoing In Vitro Characterization Recovery & Lifespan In Vitro Characterization Recovery and Survival (Grifols Sets)(n=65) (n=26) (Grifols Sets) (Fenwal Sets)(n=65) (Fenwal Sets)(n=24) Report in Progress Completed Report in Progress
Slide 28: 2025 Financial Results
2025 Financial Results 28 Not to be Reproduced
Slide 29: Record Q4 and Full Year 2025 Product Revenue
Record Q4 and Full Year 2025 Product Revenue Quarterly Product Revenue Product Revenue $60.0 • Q4:25 product revenue of $57.8 million, $55.0 +14% year-over-year (Y/Y) • North American product revenue growth $50.0 of 5% Y/Y $45.0 millions • EMEA reported product revenue growth of 36% Y/Y; non-GAAP, e
Slide 30: Seventh Consecutive Quarter of Positive Non-GAAP Adjusted EBITDA
Seventh Consecutive Quarter of Positive Non-GAAP Adjusted EBITDA‡ UNAUDITED RECONCILIATION OF NON-GAAP ADJUSTED EBITDA $ millions Q1:24 Q2:24 Q3:24 Q4:24 2024 Q1:25 Q2:25 Q3:25 Q4:25 2025 Net Loss Attributable to Cerus Corporation (9.7) (5.8) (2.9) (2.5) (20.9) (7.7) (5.7) - (2.2) (15.6) Adjustments
Slide 31: Cash, cash equivalents, & short-term investments
Quarterly Cash* and Operating Cash Flow Trends $100.0 $20.0 $15.0 $90.0 $10.0 Cash flow from operations $80.0 Cash, cash equivalents, & short-term investments $5.0 ($ Millions) ($ Millions) $70.0 $- $(5.0) $60.0 $(10.0) $50.0 $(15.0) $40.0 $(20.0) Q1:23 Q2:23 Q3:23 Q4:23 Q1:24 Q2:24 Q3:24 Q4:24 Q1:2
Slide 32: Cerus Corporation
Cerus Corporation Investor Relations IR@cerus.com (925) 288-6137 Not to be Reproduced